key: cord-0972863-rosc9usc authors: Kelly, J. R.; Crockett, M. T.; Alexander, L.; Haran, M.; Baker, A.; Burke, L.; Brennan, C.; O’Keane, V. title: Psychedelic science in post-COVID-19 psychiatry date: 2020-08-19 journal: Irish journal of psychological medicine DOI: 10.1017/ipm.2020.94 sha: 06c10749d53f00e4ac375e8c0d52ab5c0e6303d5 doc_id: 972863 cord_uid: rosc9usc The medium- to long-term consequences of COVID-19 are not yet known, though an increase in mental health problems are predicted. Multidisciplinary strategies across socio-economic and psychological levels may be needed to mitigate the mental health burden of COVID-19. Preliminary evidence from the rapidly progressing field of psychedelic science shows that psilocybin therapy offers a promising transdiagnostic treatment strategy for a range of disorders with restricted and maladaptive habitual patterns of cognition and behaviour, notably depression, addiction and obsessive compulsive disorder. The COMPASS Pathways (COMPASS) phase 2b double-blind trial of psilocybin therapy in antidepressant-free, treatment-resistant depression (TRD) is underway to determine the safety, efficacy and optimal dose of psilocybin. Results from the Imperial College London Psilodep-RCT comparing the efficacy and mechanisms of action of psilocybin therapy to the selective serotonin reuptake inhibitor (SSRI) escitalopram will soon be published. However, the efficacy and safety of psilocybin therapy in conjunction with SSRIs in TRD is not yet known. An additional COMPASS study, with a centre in Dublin, will begin to address this question, with potential implications for the future delivery of psilocybin therapy. While at a relatively early stage of clinical development, and notwithstanding the immense challenges of COVID-19, psilocybin therapy has the potential to play an important therapeutic role for various psychiatric disorders in post-COVID-19 clinical psychiatry. Crises induce a wide range of psychological reactions, with varying degrees of adaptability. The combination of uncertainty and social distancing induced by the COVID-19 pandemic can lead to excessive fear/ anxiety, loneliness and depressive thoughts (Holmes et al. 2020 , Luykx et al. 2020 , Vindegaard & Benros, 2020 . While the medium-to long-term mental health consequences are not yet known, an increase in psychological and psychiatric problems are predicted (Horesh & Brown, 2020 , Türközer & Öngür, 2020 , with an excess burden on vulnerable groups (Kelly, 2020) . The implementation of a range of multidisciplinary strategies across socioeconomic and psychological levels may be needed to mitigate the mental health burden of Accumulating clinical data shows that psilocybin therapy may be an effective therapeutic strategy across a range of disorders, including depression (Carhart-Harris et al. 2016 , obsessive compulsive disorder (Moreno et al. 2006 ) and addiction disorders (Garcia-Romeu et al. 2019 , Johnson et al. 2017 ). In addition, clinical trials are underway to investigate psilocybin therapy in anorexia nervosa (NCT04052568) and there may be a role for psilocybin therapy in the treatment of anxiety disorders (Weston et al. 2020) . Recent advances in psychedelic science are gradually unravelling the multimodal mechanisms underlying the therapeutic effect of psilocybin therapy (for example Carhart-Harris & Friston, 2019 , Lord et al. 2019 , Varley et al. 2020 . Psilocybin reliably alters an individual's state of consciousness, probably through agonist mechanisms at the 5-HT2A receptor, especially in the deep pyramidal cells in the cortex . The transient, dose-dependent alteration of the complex interconnected neural networks of the brain (Lord et al. 2019 , Varley et al. 2020 encompassing the self-reflecting 'ego', induced by psilocybin, can lead to profound experiences of connectivity to others and the environment , Griffiths et al. 2006 , Grob et al. 2011 , Kettner et al. 2019 , Smigielski et al. 2019 ) and can be harnessed by psilocybin therapy to re-conceptualise restricted and maladaptive habitual patterns of cognition and behaviour. As such, psilocybin therapy provides a translatable, transdiagnostic treatment strategy that can be further refined by a precise-personalised approach (Kelly et al. 2017 , Lewis et al. 2020 , 2020 , Studerus et al. 2012 ). Advancing precise-personalised psilocybin therapy is of particular importance given the individual variation in responses, high rates of relapse in psychiatric disorders and contraindication in psychotic and manic conditions . It has been suggested that internalising disorders may be a useful broad construct for the therapeutic application of psilocybin therapy . Moreover, given the transdiagnostic potential, a dimensional framework (Insel, 2014 ) that aligns with bio-psycho signatures could also be leveraged to enhance the targeted application of psilocybin therapy and further unravel the mechanisms underpinning the acute and persistent therapeutic effects. Indeed, further exploration of psilocybin's impact on neuroimmunoendocrine pathways (Galvão et al. 2018 , Hasler et al. 2004 , Nau et al. 2013 , Strajhar et al. 2016 , Szabo, 2015 , including the microbiomegut-brain axis, may provide additional insights into the persisting therapeutic effects (Kelly et al. 2019c , Kuypers, 2019 . Notwithstanding the limitations of animal models in fully capturing the different aspects of psilocybin therapy (Jefsen et al. 2019 , Meinhardt et al. 2020 , preclinical data have shown that serotonergic psychedelics, including psilocybin, can induce hippocampal neurogenesis (Catlow et al. 2013 , Morales-Garcia et al. 2017 , Vaidya et al. 1997 , promote dendritic spine growth and stimulate synapse formation in the prefrontal cortex (González-Maeso et al. 2007 , Ly et al. 2018 . Preclinical data also suggest that psychedelics lead to 5-HT2A receptor-mediated glutamate release (Ly et al. 2018) , and a recent magnetic resonance spectroscopy study in healthy humans found that psilocybin administration was associated with increased glutamate in the medial prefrontal cortex (Mason et al. 2020) . Researchers from the Center for Psychedelic and Consciousness Research at Johns Hopkins University recently focussed on the claustrum, a thin sheet of grey matter, embedded in the white matter of the cerebral hemispheres and situated between the putamen and the insular cortex, with a rich supply of 5-HT2A receptors and glutamatergic connectivity to the cerebral cortex, and thought to be associated with cognitive task switching (Barrett et al. 2020b , Krimmel et al. 2019 . Psilocybin acutely reduced claustrum activity and altered its connectivity with the default mode network and frontoparietal task control network, in a study involving 15 healthy volunteers, thus implicating this region as a key mediator in psilocybin therapy (Barrett et al. 2020b ). The same research group, in an open-label pilot study of 12 healthy volunteers, showed that psilocybin reduced both negative affect and amygdala responses to emotional stimuli 1 week after psilocybin, whereas by 1 month after psilocybin the responses returned to baseline (Barrett et al. 2020a) . At both 1 week and 1 month after psilocybin, there were global increases in brain functional connectivity (Barrett et al. 2020a) . A previous study in healthy controls also showed reduced amygdala reactivity, particularly on the right side, to negative and neutral stimuli due to psilocybin (Kraehenmann et al. 2015) . In contrast, an open-label study of 19 subjects with treatment-resistant depression (TRD) showed that psilocybin increased amygdala responses to emotional faces and decreased functional connectivity between the ventromedial prefrontal cortex and the right amygdala 1 day after psilocybin . Larger studies may be needed to resolve the complexities. In the midst of this evolving 'Psychedelic Revolution in Psychiatry' ) and potential increasing recreational psychedelic use, albeit from 0.55% in 2015 to 0.86% in 2018, in a sample of 168,000 members of the public (Yockey et al. 2020) , the Royal Australian and New Zealand College of Psychiatrists (RANZCP) recently published a clinical memorandum on the 'Therapeutic use of psychedelic substances' (RANZCP, 2020). This memorandum acknowledges not only the emerging therapeutic potential of psychedelics but also the need for more efficacy and safety data, particularly on potential long-term effects, to inform future potential use in psychiatric practice. In terms of acceptability and tolerability, results from the Global Drug Survey (2019) of 85,000 people showed only 18% of those surveyed, who have never used psychedelics, said they would accept psilocybin therapy for depression or PTSD, increasing to 59% in those who had previously tried psychedelics (Winstock & Johnson, 2019) . The reported fears related to 'brain damage and bad trips' (Winstock & Johnson, 2019) . Psilocybin therapy data from John Hopkins University, over a 16-year period, encompassing 250 volunteers and 380 sessions, reported no major psychological issues, with 0.9% of volunteers experiencing minor and transient psychological issues (Carbonaro et al. 2016) . However, high-quality clinical data on the long-term effects of psychedelics are lacking. For example, there is very limited data on hallucinogen-persisting perception disorder (HPPD), a rare condition that involves the continued presence of sensory disturbances (Halpern et al. 2018; Martinotti et al. 2018; Orsolini et al. 2017) . A review by Halpern and colleagues suggests that HPPD is, in most cases, due to a 'subtle over-activation of predominantly neural visual pathways that worsens anxiety after ingestion of arousal-altering drugs, including non-hallucinogenic substances' (Halpern et al. 2018) . The authors note that a personal or family history of anxiety and pre-drug use complaints of tinnitus, eye floaters and concentration problems may predict vulnerability for HPPD (Halpern et al. 2018) . Similarly, the impact of regular psychedelic use on the brain is limited (Bouso et al. 2015; Halpern et al. 2005) . Although, it is important to note that psilocybin therapy studies do not use regular dosing, using between 1 and at most 3 doses of psilocybin. Dublin is one of the clinical trial centres participating in a double-blind randomised controlled phase 2b COMPASS trial of psilocybin therapy in TRD (COMP001) (Kelly et al. 2019a) . Results from this large scale trial, and others, will address concerns regarding psilocybin safety, efficacy and dose optimisation. Moreover, we eagerly await the results from the potentially paradigm shifting, double-blind trial of psilocybin therapy versus the selective serotonin reuptake inhibitor (SSRI) escitalopram in depression from the Centre for Psychedelic Research at Imperial College London (Psilodep-RCT, NCT03429075) and acknowledge that for some people with depression, SSRIs and psilocybin may become 'competitive options' despite postulated mechanistic complementarity, with SSRIs enhancing 5-HT1AR pathway and psilocybin enhancing the 5-HT2AR pathway (Carhart-Harris & Nutt, 2017) . However, many people with depression may choose to remain on antidepressants (Kelly et al. 2019b) and it is important to determine the safety and efficacy of this approach. 5-HT2AR antagonists, such as ketanserin, block the therapeutic effect of psilocybin (Preller et al. 2017) , whereas the partial 5-HT1A agonist buspirone may exert inhibitory effects . However, apart from anecdotal evidence suggesting a blunted effect , psilocybin therapy in conjunction with SSRI's has never been investigated in TRD. The gradual emergence from COVID-19 lockdown will see the launch of a new COMPASS clinical study (COMP003) in Dublin and San Diego to determine the antidepressant effect of psilocybin therapy in people with TRD who continue SSRI medication. This exploratory open-label trial will aim to recruit 20 participants with a single or recurrent episode of at least moderate clinical depression between 3 months and 2 years duration that has not responded to an adequate dose and duration of at least two pharmacological treatments. A single dose of oral psilocybin of 25mg will be administered with psychological support to participants who have been taking an SSRI's for at least 6 weeks. The results of this study could have important practical implications for the future of psilocybin therapy and may have implications for future phase 3 trials in TRD, which could pave the way for the integration of psilocybin therapy into clinical psychiatry. However, both clinical and research psychiatry have been transformed by COVID-19, demanding additional strategies to overcome the considerable challenges (O'Brien & McNicholas, 2020; Türközer & Öngür, 2020) . To mitigate the spread of COVID-19 and facilitate the safe reopening and progress of ongoing psilocybin trials, in line with local and national guidelines, a number of measures will be implemented. These include, for example, participant and researcher respiratory symptom checklists, regular temperature checks, access to COVID-19 testing (if indicated), meticulous attention to extra hygiene measures, personal protective equipment (where not expected to negatively impact the participant's experience), and the option of remote study visits (where possible by the protocol). Notwithstanding the challenges and the early stage of clinical development, psilocybin therapy, at the forefront of translational neuroscience and psychiatry, is likely to play an important therapeutic role for certain conditions in post-COVID-19 clinical psychiatry. Financial support COMP001 and COMP003 are funded by COMPASS Pathways. Authors have no conflicts of interest to disclose. The Cork Clinical Research Ethics Committee approved COMP001 and COMP003. The authors assert that all procedures contributing to this work comply with the ethical standards of the Cork Clinical Research Ethics Committee and with the Helsinki Declaration of 1975, as revised in 2008. Emotions and brain function are altered up to one month after a single high dose of psilocybin Psilocybin acutely alters the functional connectivity of the claustrum with brain networks that support perception, memory, and attention Chronic administration of serotonergic antidepressants attenuates the subjective effects of LSD in humans Alterations in responses to LSD in humans associated with chronic administration of tricyclic antidepressants, monoamine oxidase inhibitors or lithium Long-term use of psychedelic drugs is associated with differences in brain structure and personality in humans Survey study of challenging experiences after ingesting psilocybin mushrooms: acute and enduring positive and negative consequences Psilocybin with psychological support for treatmentresistant depression: six-month follow-up Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study REBUS and the anarchic brain: toward a unified model of the brain action of psychedelics Serotonin and brain function: a tale of two receptors Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning Psilocybin-assisted psychotherapy for the treatment of Major Depressive Disorder: Preliminary results from a randomized controlled trial Effects of psilocybin therapy on personality structure Cortisol modulation by ayahuasca in patients with treatment resistant depression and healthy controls Cessation and reduction in alcohol consumption and misuse after psychedelic use Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance Pilot study of psilocybin treatment for anxiety in patients with advanced-stage CancerPsilocybin for anxiety in advancedstage cancer A review of hallucinogen persisting perception disorder (HPPD) and an exploratory study of subjects claiming symptoms of HPPD Psychological and cognitive effects of long-term peyote use among Native Americans Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebocontrolled dose-effect study Multidisciplinary research priorities for the COVID-19 pandemic: a call for action for mental health science Traumatic stress in the age of COVID-19: a call to close critical gaps and adapt to new realities The NIMH Research Domain Criteria (RDoC) project: precision medicine for psychiatry Psilocybin lacks antidepressant-like effect in the Flinders Sensitive Line rat Longterm follow-up of psilocybin-facilitated smoking cessation Coronavirus disease: challenges for psychiatry The psychedelic renaissance: the next trip for psychiatry? Dimensional thinking in psychiatry in the era of the Research Domain Criteria (RDoC) Mood matters: a national survey on attitudes to depression Mood and microbes: gut to brain communication in depression From Egoism to Ecoism: psychedelics increase nature relatedness in a state-mediated and context-dependent manner Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers Resting state functional connectivity and cognitive task-related activation of the human claustrum Psychedelic medicine: the biology underlying the persisting psychedelic effects Rostral anterior cingulate thickness predicts the emotional psilocybin experience Dynamical exploration of the repertoire of brain networks at rest is modulated by psilocybin Psychiatry in times of the coronavirus disease 2019 (COVID-19) pandemic: an imperative for psychiatrists to act now Psychedelics promote structural and functional neural plasticity Hallucinogen persisting perception disorder: etiology, clinical features, and therapeutic perspectives Me, myself, bye: regional alterations in glutamate and the experience of ego dissolution with psilocybin Psilocybin and LSD have no long-lasting effects in an animal model of alcohol relapse Therapeutic mechanisms of psilocybin: changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression The alkaloids of Banisteriopsis caapi, the plant source of the Amazonian hallucinogen Ayahuasca, stimulate adult neurogenesis in vitro Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder Serotonin 5-HT2A receptor activation blocks TNF-α mediated inflammation in vivo The current status of psychedelics in psychiatry Psychedelic psychiatry's brave new world The use of telepsychiatry during COVID-19 and beyond Mental Health Impacts of COVID-19 in Ireland and the Need for a Secondary Care The "Endless Trip" among the NPS users: psychopathology and psychopharmacology in the hallucinogen-persisting perception disorder. A systematic review Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience Psilocybin induces time-dependent changes in global functional connectivity Psychedelic Science in post-COVID-19 psychiatry 5 The fabric of meaning and subjective effects in LSD-induced states depend on Serotonin 2A receptor activation Effects of serotonin 2A/1A receptor stimulation on social exclusion processing The Royal Australian and New Zealand College of Psychiatrists (RANZCP) Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression Psilocybin-assisted mindfulness training modulates self-consciousness and brain default mode network connectivity with lasting effects Acute effects of lysergic acid diethylamide on circulating steroid levels in healthy subjects Prediction of psilocybin response in healthy volunteers Psychedelics and Immunomodulation: Novel Approaches and Therapeutic Opportunities A projection for psychiatry in the post-COVID-19 era: potential trends, challenges, and directions 5-HT2A receptor-mediated regulation of brain-derived neurotrophic factor mRNA in the hippocampus and the neocortex Serotonergic psychedelics LSD & psilocybin increase the fractal dimension of cortical brain activity in spatial and temporal domains COVID-19 pandemic and mental health consequences: Systematic review of the current evidence Historic psychedelic drug trials and the treatment of anxiety disorders Global Drugs Survey: The psychedelic revolution in psychiatry and why patient opinion matters so much Trends in LSD use among US adults